Victoria L. Bae-Jump

Gynecologic Oncology | Oncology

101 Manning Dr
Chapel Hill, NC 27514

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 161 publications

Development of a patient navigation intervention for rural patients diagnosed with endometrial cancer: An intervention mapping approach.

Development of a patient navigation intervention for rural patients diagnosed with endometrial cancer: An intervention mapping approach.

Journal: Women's health (London, England)

Published: August 25, 2026

Retraction: JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.

Retraction: JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.

Journal: Oncotarget

Published: April 24, 2026

Retraction: JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.

Retraction: JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.

Journal: Oncotarget

Published: April 24, 2026

Diagnostic Timing and Ovarian Cancer Survival.

Diagnostic Timing and Ovarian Cancer Survival.

Journal: JAMA network open

Published: March 27, 2026

Pre-diagnosis symptoms reported among endometrial cancer survivors.

Pre-diagnosis symptoms reported among endometrial cancer survivors.

Journal: Gynecologic oncology reports

Published: March 23, 2026

Perceived Discrimination and Healthcare System Trust as Barriers to Survivorship Care in Endometrial Cancer.

Perceived Discrimination and Healthcare System Trust as Barriers to Survivorship Care in Endometrial Cancer.

Journal: Cancer medicine

Published: March 23, 2026

Eicosapentaenoic Acid Suppresses Tumor Growth and Enhances Chemosensitivity via AKT/mTOR Signaling in Uterine Serous Carcinoma.

Eicosapentaenoic Acid Suppresses Tumor Growth and Enhances Chemosensitivity via AKT/mTOR Signaling in Uterine Serous Carcinoma.

Journal: Cancers

Published: March 05, 2026

MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.

MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.

Journal: Gynecologic oncology

Published: February 15, 2026

Neighborhood Socioeconomic Deprivation and Perceived Discrimination Among Endometrial Cancer Survivors.

Neighborhood Socioeconomic Deprivation and Perceived Discrimination Among Endometrial Cancer Survivors.

Journal: Psycho-oncology

Published: January 17, 2026

Impact of Allostatic Load on Overall Survival in Patients With Endometrial Cancer.

Impact of Allostatic Load on Overall Survival in Patients With Endometrial Cancer.

Journal: Cancer medicine

Published: December 10, 2025

A novel ex vivo platform for functional evaluation of treatment responses in metastatic ovarian cancer.

A novel ex vivo platform for functional evaluation of treatment responses in metastatic ovarian cancer.

Journal: NPJ precision oncology

Published: October 29, 2025

Immune-Related Adverse Events Among Patients With Endometrial Cancer Receiving Pembrolizumab Alone or With Other Treatments: A Single-Center Real-World Experience.

Immune-Related Adverse Events Among Patients With Endometrial Cancer Receiving Pembrolizumab Alone or With Other Treatments: A Single-Center Real-World Experience.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: October 28, 2025

Showing 1-12 of 161

Last Updated: 09/26/2026